Christin Glorioso, MD PHD

Christin Glorioso, MD PHD is a physician-scientist, entrepreneur, and advocate for brain longevity who serves as the CEO and Co-founder of NeuroAge Therapeutics.1 Her company focuses on rejuvenating brain aging to keep people sharp and treat neurodegenerative diseases, with a particular emphasis on creating drugs to address Alzheimer's disease.13

Background and Education

Dr. Glorioso received her MD/PhD from the University of Pittsburgh School of Medicine, specializing in neuroscience. She also holds a Bachelor of Science in Cell and Molecular Biology from the University of Michigan. Following her education, she completed her postdoctoral training at MIT, where she studied brain aging and Alzheimer's disease in the Guarente Lab.3

Professional Experience

Before founding NeuroAge Therapeutics in April 2022, Dr. Glorioso held several notable positions:

• Research Scientist and Postdoctoral Associate at MIT (2012-2020)2
• Chief Strategist at the Bakar Aging Research Institute (BARI) at the University of California, San Francisco3
• Head of AI for the COVID initiative at TeachAids, a Stanford spin-off non-profit
• Head of Research for the Data Informatics Center for Epidemiology (DICE) at the PathCheck Foundation

Entrepreneurial Ventures

In addition to NeuroAge Therapeutics, Dr. Glorioso has founded and co-founded several organizations:

• Longevity Global: Founder and Executive Director (March 2022 - Present)2
• Academics for the Future of Science: Co-founder and CEO (January 2013 - Present)2
• MIT Think Tank: Co-founder (August 2013 - August 2015)2

Approach to Brain Aging

At NeuroAge Therapeutics, Dr. Glorioso and her team are pioneering a new approach to treating neurodegenerative disorders by creating the first aging clock specific to the brain.1 They examine data from human brains to identify patterns in biology that change as people age, which has led to the discovery of promising targets for potential treatments.1

Dr. Glorioso's commitment to fighting brain aging stems from a personal connection, as her grandmother passed away from Alzheimer's disease when she was a child.3 This experience has driven her lifelong commitment to creating better therapies to prevent and treat Alzheimer's and other neurodegenerative diseases.3